| Autor: |
Zhen-Yu Li, Ying-Li Dong, Xiao-Zhong Cao, Sha-Sha Ren, Zhen Zhang |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Clinical and Experimental Obstetrics & Gynecology, Vol 50, Iss 4, p 74 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
0390-6663 |
| DOI: |
10.31083/j.ceog5004074 |
| Popis: |
Background: Neoadjuvant chemotherapy has become the standard treatment for patients with locally advanced breast cancer. However, patients with hormone receptor positive (especially human epidermal growth receptor 2 negative) breast cancer show low response rate to neoadjuvant chemotherapy. Whether neoadjuvant chemo-endocrine therapy (NCET) can improve the pathological complete response (pCR) rate of these patients remains controversial. Methods: A systematic literature search was conducted in the PubMed, Embase, and Cochrane databases. Pooled odds ratio (OR) with 95% confidence intervals (CI) was calculated. Results: Five randomized controlled trials were included (N = 566). NCET did not significantly improve pCR (OR 1.35, 95% CI 0.77–2.38, p = 0.30). Conclusions: NCET did not to improve the pCR rates in patients with hormone receptor positive breast cancer. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
